Barinthus Biotherapeutics plc (BRNS)

Barinthus Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	14.97	0.8	44.7	0.27	4.82
Revenue Growth (YoY)	-	1766.46%	-98.21%	16580.22%	-94.44%	-29.57%
Cost of Revenue	-10.52	1.68	2.01	42.35	20.37	14.39
Gross Profit	10.52	13.29	-1.21	2.35	-20.1	-9.57
Selling, General & Admin	30.04	23.54	39.79	6.47	25.12	10.48
Research & Development	36.58	36.57	39.4	-1.24	-4	-3.28
Other Operating Expenses	-1.25	-1.18	-	-	-	-
Operating Expenses	65.38	58.94	79.19	5.23	21.12	7.2
Operating Income	-54.86	-45.65	-80.4	-2.87	-41.22	-16.77
Interest Expense	-0.05	-0.05	-0.03	-0.02	-2.67	-3.6
Interest & Investment Income	2.19	2.68	2.88	3.1	0	-
Currency Exchange Gain (Loss)	-	-	-	-	0.21	0.45
Other Non Operating Income (Expenses)	0.21	0.14	1.08	0.57	6.33	2.08
EBT Excluding Unusual Items	-52.52	-42.89	-76.47	0.78	-37.35	-17.84
Impairment of Goodwill	-12.21	-12.21	-	-	-	-
Asset Writedown	-9.93	-5.26	-	-	-	-
Other Unusual Items	-1.41	-0.87	-0.06	0.07	-13.79	-
Pretax Income	-76.06	-61.23	-76.52	0.85	-51.14	-17.84
Income Tax Expense	-0.12	-0.04	-3.08	-4.47	-0.03	0.1
Earnings From Continuing Operations	-75.95	-61.18	-73.45	5.32	-51.11	-17.93
Minority Interest in Earnings	0.07	0.11	0.1	0.02	0.25	0.23
Net Income	-75.88	-61.07	-73.35	5.34	-50.87	-17.71
Net Income to Common	-75.88	-61.07	-73.35	5.34	-50.87	-17.71
Shares Outstanding (Basic)	40	39	38	37	26	8
Shares Outstanding (Diluted)	40	39	38	38	26	8
Shares Change (YoY)	3.60%	2.50%	0.57%	47.40%	227.59%	33580.72%
EPS (Basic)	-1.88	-1.55	-1.91	0.14	-1.96	-2.24
EPS (Diluted)	-1.88	-1.55	-1.91	0.14	-1.96	-2.24
Free Cash Flow	-30.97	-29.83	-56.34	-20.57	-33.73	-11.32
Free Cash Flow Per Share	-0.77	-0.76	-1.47	-0.54	-1.30	-1.43
Gross Margin	-	88.78%	-150.75%	5.26%	-	-198.42%
Operating Margin	-	-304.98%	-10024.69%	-6.43%	-15380.60%	-347.79%
Profit Margin	-	-408.00%	-9145.51%	11.95%	-18979.48%	-367.27%
Free Cash Flow Margin	-	-199.29%	-7024.69%	-46.01%	-12585.45%	-234.83%
EBITDA	-51.7	-43.05	-78.17	-1.75	-40.82	-16.56
EBITDA Margin	-	-287.61%	-	-3.92%	-	-
D&A For EBITDA	3.16	2.6	2.23	1.12	0.4	0.21
EBIT	-54.86	-45.65	-80.4	-2.87	-41.22	-16.77
EBIT Margin	-	-	-	-6.43%	-	-
Revenue as Reported	-	14.97	0.8	44.7	0.27	4.82

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q